Separovic L, Zhan Y, Kaweski SE, Sabaiduc S, Caraz. Interim estimates of vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2) during a delayed influenza season, Canada, 2024/25. Euro Surveill. 2025 Jan;30(4)
The Canadian Sentinel Practitioner Surveillance Network (SPSN) reports interim 2024/25 vaccine effectiveness (VE) against acute respiratory illness due to laboratory-confirmed influenza during a delayed season of predominant A(H1N1)pdm09 and lower A(H3N2) co-circulation. Through mid-January, the risk of outpatient illness due to influenza A is reduced by about half among vaccinated vs unvaccinated individuals. Adjusted VE is 53% (95% CI: 36-65) against A(H1N1)pdm09, comprised of clades 5a.2a and 5a.2a.1, and 54% (95% CI: 29-70) against A(H3N2), virtually all clade 2a.3a.1.
See Also:
Latest articles in those days:
- [preprint]The mammalian-adaptive PB2-E627K substitution preserves viral fitness of clade 2.3.4.4b H5N1 HPAIV in birds 12 hours ago
- Mallard super-shedders of avian influenza exhibit distinct cloacal microbial abundance profiles 16 hours ago
- A digitally immune-optimized influenza vaccine broadly neutralizes swine and human H1N1 influenza viruses and protects from heterologous challenge 16 hours ago
- Associations between vaccine misinformation and influenza vaccine uptake: a population-based interrupted time-series study in China 17 hours ago
- Infection and transmission dynamics of bovine and human influenza A H5N1 viruses in mouse and hamster models 18 hours ago
[Go Top] [Close Window]
